Project Grant R41CA306717
Award Date 9/18/25
Completion Date 8/31/26
Dollars Obligated $393K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Denver, CO 80220, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Seak Therapeutics, LLC to develop a potent and highly brain-penetrable antimitotic agent called SEAK193 to treat breast cancer brain metastasis. The $399,981 grant aims to further de-risk SEAK193 as a single agent and assess its viability as a clinical candidate for the effective treatment of breast cancer brain metastases, as well as brain metastases from other cancer...
- This $781,436 federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research by Cold Spring Harbor Laboratory to optimize anti-NMDAR (N-methyl-D-aspartate receptor) antibodies for the treatment of triple-negative breast cancer (TNBC). The key objectives are to: 1) establish an orthotopic mouse model of NMDAR-positive TNBC, 2) screen for anti-NMDAR antibodies that can effectively target NMDAR-positive TNBC cells while...
- This $137,322 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research by Trustees of Boston University to develop disulfated polyamidosaccharide nanoparticles as a P-selectin targeting chemotherapeutic delivery system. The goal is to create a more targeted and effective treatment for breast and lung cancers, which disproportionately affect women, including many non-smokers. The research will leverage the upregulation of P-selectin on...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Colorado-Denver to study the role of the EYA3/PP2A protein complex in regulating the metastatic spread of triple-negative breast cancer (TNBC). The $647,118 award, effective March 1, 2025 through February 28, 2030, supports research aimed at understanding how EYA3 and its interaction with the B55A subunit of PP2A contribute to TNBC metastasis. The project...
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), supports research focused on understanding the relationship between inflammatory signaling in the leptomeninges and the growth of leptomeningeal metastatic tumors. The $730,398 award to the Sloan-Kettering Institute for Cancer Research, located in New York, will leverage mouse models and single-cell RNA sequencing to investigate how cancer cell signals induce...
- This Project Grant award from the National Cancer Institute under CFDA 93.395 - Cancer Treatment Research supports research to advance the understanding of how a novel neoadjuvant therapy using an anti-Semaphorin 4D (anti-Sema4D) antibody in combination with immune checkpoint blockade (ICB) impacts the immune system in patients with refractory melanoma. The $1,419,108 award to Emory University will enable the research team to gain insights into how blocking Sema4D signaling enhances the...
- This federal Project Grant award of $584,510.00, provided by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), supports the development of advanced spatial transcriptomics and proteomics technologies for studying tumor microenvironments. The award enables the University of Colorado-Denver to implement new imaging techniques and computational approaches to enhance the capabilities of its Human Immune Monitoring Shared Resource (HIMSR). This will allow...
- This federal Project Grant award of $144,768 from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research into PIK3C2A as a potential immunotherapeutic target for triple-negative breast cancer (TNBC). The researchers at the Trustees of Indiana University, Indianapolis hypothesize that inhibiting the PIK3C2A protein can enhance tumor antigen presentation, thereby potentiating the anti-tumor effects of immune checkpoint blockade therapy for TNBC. The research...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to elucidate the comprehensive mechanism by which metastatic breast cancer induces permeability of the blood-brain barrier, thereby facilitating breast cancer brain metastases (BCBM). The $479,591 award seeks to understand how breast cancer cells secrete a glycosylated protein, Fetuin-A, to transiently open the blood-brain barrier and enable cancer cells to metastasize to the brain....